{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.8","upperLimit":"8.3","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"Relapse-free survival was assessed for participants who achieved a complete remission or complete remission with partial hematological recovery during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission.\n\nRelapse free survival was estimated using Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"MEDIAN","populationDescription":"Participants who reached complete remission or complete remission with partial hematological recovery during the core study","reportingStatus":"POSTED","timeFrame":"Up to the data cut-off date of 10 October 2013; median observation time was 8.9 months.","title":"Relapse-free Survival","type":"SECONDARY","unitOfMeasure":"months"}